Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S4W-00021 · Session 4

Whether the Scottish Medicines Consortium proposes to take action in light of the study in The New England Journal of Medicine claiming tha…

Answered Asked by Dr Richard Simpson Lab Lodged 11 May 2011

The question

To ask the Scottish Executive whether the Scottish Medicines Consortium proposes to take action in light of the study in The New England Journal of Medicine claiming that bevacizumab is as effective as ranibizumab in the treatment of wet macular degeneration.

The answer

Answered by Nicola Sturgeon on 25 May 2011 · 14 days after it was lodged, on time

The Scottish Medicines Consortium (SMC) appraises all newly licensed medicines for clinical and cost-effectiveness and publishes advice for NHSScotland. The SMC does not appraise a medicine to treat a condition for which the pharmaceutical company that manufactures it does not hold a marketing authorisation (license) for the treatment of that condition.
Whilst bevacizumab (Avastin) is licensed for the treatment of other conditions, it is not licensed for the treatment of eye conditions. Responsibility for obtaining a marketing authorisation for bevacizumab to treat wet age-related macular degeneration rests with the pharmaceutical company that manufactures it. The pharmaceutical company would then be able to submit clinical and cost-effectiveness evidence for consideration by the SMC.

In the Official Report

No contribution in the Official Report cites S4W-00021 by reference.